The Use of Intranasal Ketoralac for Pain Management (Sprix)

Montefiore Medicine Academic Health System

Status and phase: Terminated; Phase 4

Conditions: Urolithiasis; Postoperative Pain Management

Treatments: Drug: Intranasal Ketoralac; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT01736358

12-02-244

Details and patient eligibility

About

Despite an overall reduction in the perioperative complication rate, post operative pain management after ureteroscopic removal of stones (URS) remains a major factor delaying discharge of patients. The investigators hypothesize that perioperative usage of intranasal ketorolac will provide a reduction in post operative opioid requirements, better post operative pain control, higher anesthesia satisfaction and faster recovery.

Full description

The prevalence and incidence of urolithiasis, or kidney stone disease, are increasing in the general population. Life-time incidence of urolithiasis is estimated to be between 5%- 12%. The treatment of kidney stones depends on stone type and size, symptom severity, and the presence of obstruction.

URS is a common ambulatory procedure as improved technological advances and increased clinical utilization have helped decrease postoperative complications. Despite an overall reduction in the perioperative complication rate, post operative pain management after URS remains a major factor delaying discharge of patients.

Post operative pain after URS is usually treated with opioids and non steroidal anti inflammatory drugs. Intranasal ketorolac (SprixTM) is an FDA approved pain formulation for short term management (5 days) of moderate to moderately severe pain that requires analgesia at the opioid level. The efficacy of intranasal ketorolac formulation was demonstrated in placebo-controlled studies in patients following major surgeries.

The primary objective of the study is to evaluate the role perioperative usage of single-dose of intranasal ketorolac on immediate post operative opioid requirements. Secondary objectives of the study are to (a) evaluate the post operative pain score 30 minutes after surgery, 1 hour after surgery, and 2 hours after surgery, (b) find the incidence of immediate (until discharge) and 24hrs post operative side effects in the target population, (c) find the level of anesthesia satisfaction in the target population, (d) find the time to discharge in the target population, (e) compare the two groups post anesthesia discharge score.

Enrollment: 50 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Ureteroscopic stone removal surgeries with stenting
• Age ≥ 18 years and < 65 years
• Stable patient with stable vital signs
• Mentally competent and is able to understand consent form

Exclusion criteria

• Unstable patients
• Patients with multiple trauma sites
• Patients with allergies to ketorolac or any of the components in the nasal spray preparation
• Patients with active peptic ulcer disease
• History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs
• Renal disease or at risk for renal failure due to volume depletion
• Pregnant or nursing mothers
• Nasal abnormality or illness that could affect the absorption of intranasal medication (such as: nasal discharge, rhinitis, acute upper respiratory infection, acute epistaxis, nasal polyp, nasal tumor)
• Any other contraindication to the use of Sprix, or in whom use of Sprix would not be consistent with the approved package insert

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

50 participants in 2 patient groups, including a placebo group

Intranasal Ketoralac

Experimental group

Description:

A single dose of Sprix (31.5 mg) will be administered to patients 20 minutes before the end of surgery. 15.75 mg of Sprix will be sprayed in each nostril.

Treatment:

Drug: Intranasal Ketoralac

Placebo

Placebo Comparator group

Description:

A single dose of placebo will be administered 20 minutes before the end of surgery. 15.75 mg of the placebo will be sprayed in each nostril.

Treatment:

Drug: Placebo